RNAi Therapeutics Developers have Undertaken Several Partnership Initiatives
by Roots Analysis Roots Analysis provides market research and consulIn the recent past, several companies have
collaborated with other industry players / research institutes to develop novel
RNAi based products. According to our research, most of the deals inked in this
upcoming field of research were observed to be associated with the development
of adequate delivery systems and technology platforms for RNAi based
interventions.
R&D agreements were the most common type
of partnership model adopted by players in the RNAi
therapeutics domain, representing 32% of the total number of deals
established in the given time period. This is followed by licensing agreements
and mergers and acquisitions. Recent examples of licensing agreements include (in
reverse chronological order) collaboration between Phio Pharmaceuticals and
Helmholtz Zentrum München (August 2019), Silence Therapeutics and Genomics
England (May 2019), Phio Pharmaceuticals and Glycostem Therapeutics (March
2019), and Alnylam Pharmaceuticals and CAMP4 Therapeutics (January 2019).
Most of the partnerships (48%) were
observed to be focused on developing drugs based on siRNA molecule. This can be
attributed to the fact that the aforementioned technology offers high
specificity with one mRNA target. Recent examples of agreements signed for siRNA include (in reverse
chronological order) those signed between
Alnylam Pharmaceuticals and Ironwood Pharmaceuticals (August 2019), Silence
Therapeutics and Mallinckrodt
Pharmaceuticals (July 2019), Alnylam Pharmaceuticals and GENESIS Pharma
(July 2019), Alnylam Pharmaceuticals and Regeneron Pharmaceuticals (April 2019)
and Alnylam Pharmaceuticals and Medison
Pharma (January 2019). Further, it is important to highlight that significant
number of collaborations (17%) have been signed for derivatives of siRNA, the
self-deliverable molecules.
Most of the agreements (60%) were signed between industry players located in the same region (53% in North America, 3% in Europe and 4% in Asia-Pacific). Furthermore, in most of the intercontinental agreements, the leading partner was observed to be based in North America, while its collaborator was a player based in Europe (15%). This is followed by agreements, wherein companies (leading partner) from Asia Pacific have collaborated with players based in North America (15%). A similar observation was made across 3% of instances, wherein players based in North America entered into deals with companies headquartered in the Asia Pacific.
Sponsor Ads
Created on Jun 30th 2020 04:29. Viewed 275 times.